Table of contents


On 13 April 2007, orphan designation (EU/3/07/444) was granted by the European Commission to Oxford Regulatory Solutions Ltd, United Kingdom, for pralatrexate for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).

The sponsorship was transferred to European Medical Advisory Services Limited, United Kingdom, in December 2007 and subsequently to Allos Therapeutics Limited, United Kingdom, in April 2010.

Key facts

Active substance
Disease / condition
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Date of first decision
EU designation number

Sponsor's contact details

Allos Therapeutics Limited
71 Knowl Piece
Wilbury Way
Hertfordshire SG4 OTY
United Kingdom
Telephone: +44 1462 424 416
Telefax: +44 1462 600 453

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating